Real-world effectiveness of nirmatrelvir/ritonavir against COVID-19 hospitalizations and severe COVID-19 in community-dwelling elderly Singaporeans during …
LE Wee, AT Tay, C Chiew, BE Young, B Wong… - Clinical Microbiology …, 2023 - Elsevier
Objectives Real-world data on continued effectiveness of nirmatrelvir/ritonavir against
hospitalization and severe COVID-19 in the context of widespread booster mRNA vaccine …
hospitalization and severe COVID-19 in the context of widespread booster mRNA vaccine …
Clinical effectiveness of oral antiviral agents in older patients with COVID‐19 based on real‐world data
Several randomized controlled trials and real‐world cohort studies have demonstrated the
efficacies of nirmatrelvir plus ritonavir (NMV‐r) and molnupiravir (MOV) in at‐risk patients …
efficacies of nirmatrelvir plus ritonavir (NMV‐r) and molnupiravir (MOV) in at‐risk patients …
[HTML][HTML] Protective effect of ursodeoxycholic acid on COVID-19 in patients with chronic liver disease
Y Li, N Zhu, X Cui, Y Lin, X Li - Frontiers in Cellular and Infection …, 2023 - frontiersin.org
Objective: Ursodeoxycholic acid (UDCA) may reduce susceptibility to severe acute
respiratory syndrome coronavirus-2 (SARS-CoV-2) infection by downregulating host …
respiratory syndrome coronavirus-2 (SARS-CoV-2) infection by downregulating host …
Symptoms, Viral Loads, and Rebound Among COVID-19 Outpatients Treated With Nirmatrelvir/Ritonavir Compared With Propensity Score–Matched Untreated …
SE Smith-Jeffcoat, JE Biddle, HK Talbot… - Clinical Infectious …, 2024 - academic.oup.com
Abstract Background Nirmatrelvir/ritonavir (N/R) reduces severe outcomes from coronavirus
disease 2019 (COVID-19); however, rebound after treatment has been reported. We …
disease 2019 (COVID-19); however, rebound after treatment has been reported. We …
Effectiveness, tolerability and prescribing choice of antiviral molecules molnupiravir, remdesivir and nirmatrelvir/r: a real-world comparison in the first ten months of use
C Del Borgo, S Garattini, C Bortignon, A Carraro… - Viruses, 2023 - mdpi.com
In 2022, three antiviral drugs—molnupiravir, remdesivir and nirmatrelvir/ritonavir—were
introduced for treatment of mild-to-moderate COVID-19 in high-risk patients. The aim of this …
introduced for treatment of mild-to-moderate COVID-19 in high-risk patients. The aim of this …
Real-world Effectiveness of Molnupiravir and Nirmatrelvir/Ritonavir as Treatments for COVID-19 in Patients at High Risk
D Paraskevis, M Gkova, K Mellou… - The Journal of …, 2023 - academic.oup.com
Background Using a retrospective cohort study design, we aimed to evaluate the
effectiveness of molnupiravir and nirmatrelvir/ritonavir in patients with SARS-CoV-2 who …
effectiveness of molnupiravir and nirmatrelvir/ritonavir in patients with SARS-CoV-2 who …
China's COVID-19 reopening measures—warriors and weapons
S Huang, Z Gao, S Wang - The Lancet, 2023 - thelancet.com
China's COVID-19 reopening measures�warriors and weapons Page 1
Correspondence www.thelancet.com Vol 401 February 25, 2023 643 his inauguration. We …
Correspondence www.thelancet.com Vol 401 February 25, 2023 643 his inauguration. We …
P21-activated kinase 1 (PAK1)-mediated cytoskeleton rearrangement promotes SARS-CoV-2 entry and ACE2 autophagic degradation
M Liu, B Lu, Y Li, S Yuan, Z Zhuang, G Li… - … and Targeted Therapy, 2023 - nature.com
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of
coronavirus disease 2019 (COVID-19), has had a significant impact on healthcare systems …
coronavirus disease 2019 (COVID-19), has had a significant impact on healthcare systems …
Efficacy and safety of antiviral treatments for symptomatic COVID-19 outpatients: Systematic review and network meta-analysis
M Zur, T Peselev, S Yanko, V Rotshild, I Matok - Antiviral Research, 2023 - Elsevier
Background Remdesivir, molnupiravir, and nirmatrelvir/ritonavir are three antiviral agents
approved by FDA emergency authorization for treating mild to moderate symptomatic COVID …
approved by FDA emergency authorization for treating mild to moderate symptomatic COVID …
The Landscape of Antiviral Therapy for COVID-19 in the Era of Widespread Population Immunity and Omicron-Lineage Viruses
EA Meyerowitz, Y Li - Clinical Infectious Diseases, 2024 - academic.oup.com
The goals of coronavirus disease 2019 (COVID-19) antiviral therapy early in the pandemic
were to prevent severe disease, hospitalization, and death. As these outcomes have …
were to prevent severe disease, hospitalization, and death. As these outcomes have …